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Langerhans cells (LCs) may be involved in the immunosurveillance against tumors as antigen-presenting cells. Our objective has
been to determine the relevance of LC in progression of larynx squamous cell carcinomas and their relationship with diﬀerent
subpopulations of tumor-inﬁltrating cells. LCs were investigated by immunohistochemical methods using anti-CD1 antibody. LCs
weredetectedinmostoftheprimarytumorsstudied(44outof50)andalsoinmetastases(6outof10)andrecurrences(2outof3),
but we did not ﬁnd any statistical association between number of LCs and clinical-pathological parameters or survival. However,
the number of LCs was increased in patients with evident inﬁltration of lymphocytes, mainly cytotoxic T cells. We can conclude
that although LCs did not show clinical utility as prognostic marker, they may play a role in releasing an active immune response
in larynx carcinomas, according to their ability to present antigens to sensitized T cells.
1.Introduction
Laryngeal squamous cell carcinomas display a limited and
staged tendency to metastasize. This behaviour raises the
question of whether local mechanisms exist inside the larynx
whichplayaprotectiverolebyrecognizingandinhibitingthe
spreadofneoplasticcells.ItiswellknownthatTlymphocytes
are the major cells involved in tumor cell kill, although T
cells need to be activated by antigen presentation. One of the
antigen-presenting cells is the Langerhans cells that consti-
tute a small subpopulation (3–8%) of epidermal cells with
dendriticprocesses.Inaddition,LCshavereceptorsfortheFc
portion of IgG and the complement component C3b. Lang-
erhans cells are characterized by two types of markers: an ul-
trastructuralmarker,theBirbeckgranule,anddiﬀerentmem-
brane markers: HLA-DR antigens, S-100 protein and CD1a.
Antigen-presenting Langerhans cells are now considered
a population of cells of bone marrow origin [1], which pick
up antigens encountered in the squamous epithelia of lar-
ynx and to migrate subsequently to the draining lymph
nodes. Upon arrival in the paracortex of lymph nodes, the
antigen-laden LCs transform into interdigitating cells and
they present antigen to naive T lymphocytes. In addition
LCs have the capacity to present complex protein antigens
such as puriﬁed protein derivative of tuberculin and herpes
simplex virus antigen to lymphocytes [1]. Therefore LCs
may be involved in immunosurveillance against neoantigens
associated with malignant transformation by transporting
antigens to local lymph and presenting them to speciﬁc T
cells. Furthermore, there is an increasing body of evidence
supporting the hypothesis that LCs have a role in the immu-
nosurveillance against a number of diﬀerent tumors, such as
nasopharyngeal carcinoma, gastric carcinoma, or papillary
thyroid carcinoma [2–4].
A relationship between LCs and prognosis has been
published in a number of diﬀerent tumors [5, 6] raising2 Journal of Oncology
the question of whether LCs have a role in the immuno-
surveillance against cancer. However, there are surprisingly
fewreportsinvestigating thepresenceandsigniﬁcanceofLCs
in laryngeal tumors [7–9], one of the commonest cancers in
the Mediterranean area. Our study is the ﬁrst report of the
association between LCs and the diﬀerent subpopulations of
tumor-inﬁltratingleukocytesinsquamouscellcarcinomasof
the larynx. For this purpose we used a panel of monoclonal
antibodies (Moabs) and immunohistochemistry techniques.
LCs were detected in most of the tumors studied and also in
metastases or recurrences. The presence of these cells in the
metastases is another evidence of their extraepidermal origin
and their relationship with antitumoral mechanisms. The
number of LCs present only yielded signiﬁcance in relation
tootherleukocytesubpopulations,emphasizingthatLCscan
serve as an indicator of defence of the host against the larynx
carcinoma. The function of LCs in tumor immunobiology is
discussed.
2.MaterialandMethods
2.1. Patients. All the patients were treated according to
a relatively uniform philosophy during the study period.
Surgery consisted predominantly of total laryngectomy and
horizontal supraglottic laryngectomy in selected cases. Neck
dissection was carried out in clinical stage IV disease and
in stage III disease as indicated by the presence of cervical
metastases and the speciﬁc site of the primary tumor.
Twenty-seven tumors (54%) were classiﬁed as supraglottic,
14 glottic (28%), 2 (4%) subglottic, 4 (8%) transglottic
and 3 (6%) were pyriform sinus carcinomas. All were male
and none of the patients had received radiotherapy and/or
chemotherapy prior to surgery. The youngest patient was
44 years old and the oldest 75 years old (mean age, 58
years). All were male. Diagnosis was conﬁrmed in paraﬃn
sections. Tumors were classiﬁed into 3 grades—Broders,
modiﬁcation by WHO (World Health Organization)—and
all were scored according to Glanz’s [10] and Jakobsson’s
grading for squamous cell cancer [11]. Cases were also
carefully staged to conform to the 1995 criteria of the
American Joint Committee for Cancer Staging and End
Results Reporting. T-stage was recorded as follows: 4 (8%)
T1, 4 (8%) T2, 30 (60%) T3 and 12 (24%) T4. N-stage: 34
N 0( 6 8 % ) ,4N 1( 8 % ) ,5N 2( 1 0 % ) ,7N 3( 1 4 % ) ,a n di n
two cases neck exploration was not available in the clinical
notes. The histological analyses were performed without any
knowledge of the clinical stage, treatment, or the further
course of the disease. Longest followup ranged between 96
and 144 months. Patients gave informed consent which
was noted in the clinical history. All procedures followed
the ethical standards of the hospital committee on human
experimentation and the Helsinki Declaration (1975, 1983).
2.2.MonoclonalAntibodies. ThefollowingMoabswereused:
GRB1 against DR antigen; GRT2, which recognizes the
common leukocyte antigen CD45; Leu 4, Leu 3a, Leu 2a,
against CD3, CD4, CD8, respectively, (Becton Dickinson),
Rutherford, NJ); Bear-1 against CD11b; OKT6 against CD1
(Ortho, Raritan, NJ); IOM-1 against CD20 (Immunotech,
Marseille, France).
2.3. Immunohistochemical Analysis. Binding of Moabs to
frozen sections was assayed by the techniques of alka-
line immunophosphatase and streptavidin-biotin. Details
of the methods and sample processing have been pub-
lished elsewhere [12, 13]. Sections were examined with an
Olympus BH-2 microscope. The intensity, composition and
distribution of the inﬂammatory inﬁltrate were examined
both qualitatively and quantitatively in all sections by two
observers. Cellular inﬁltrate in both tumor stroma and
tumor parenchyma was assessed by counting lymphoretic-
ular cells in each tissue compartment in a minimum of ten
microscopic high power ﬁelds and averaged.
2.4. Statistical Analysis. Statistical correlations were calcu-
lated using the BMDP (biomedical data processing) package
from UCLA (University of California, Los Angeles, 1985
version). The parameters included in the study are listed in
Table 2. First, tumors were divided in two groups according
to the mean value of LCs per 10 high-power ﬁelds (HPFs),
whichwasfoundtobe7.32:tumorswithlessthan7LCs/HPF
and tumors presenting more than 7 LCs/HPF. A chi-squared
test and, whenever appropriate, Fisher’s exact test were
applied for analysis of contingency tables. The analysis of
the variance test was used for continuous variables (natural
log transformed when necessary). Survival was estimated
by the Kaplan and Meier method, and survival curves were
compared with the log rank test. Cox’s proportional hazards
survival analysis was used to determine the relative risk in
multivariate analysis.
3. Results
LCs were present in most of the primary tumors investigated
(44 out of 50 cases) ranging from 0.6 to 18.3 (mean 7.32,
standard deviation 4.5). The presence of LCs was detected
in all mucosa samples distant to tumor from the patients
(Figure 1) which were found to be polystratiﬁed epithelia,
more often keratinized. The number of LCs varied according
to the thickness of the mucosal layer and the degree of kera-
tinization. Theyweremorefrequentlyfoundinpolystratiﬁed
andkeratinizedepithelia.LCswerealsofoundinlymphnode
metastases (6 out of 10) and recurrences (2 out of 3).
When analyzing the relationship between number of LCs
and the parameters studied, Langerhans cells were increased
in patients with evident inﬁltration of lymphocytes, mainly
cytotoxic T lymphocytes (Figure 1,T a b l e1). Thus, an
increase in LCs was signiﬁcantly associated with an increase
in number of leukocytes, cytotoxic T lymphocytes and B-
cells, but a decrease in the number of macrophages and in
the ratio of CD4/CD8, which emphasize the role of LCs as
antigen-presenting cells.
Ontheotherhand,wewerenotabletoﬁndanystatistical
association between clinical-pathological parameters, prog-
nosis and number of LCs (Tables 2 and 3).Journal of Oncology 3
(a) (b)
(c) (d)
Figure 1: Immunostaining of Langerhans cells (CD1) in a larynx normal tissue (a) and paraﬃn sections of a epidermoid carcinoma of
larynx stained with H&E (b) and immunostained for Langerhans cells (CD1) (c) and cytotoxic T lymphocytes (CD8) (d).
Table 1: Relationship between LCs and subpopulations in tumor-
inﬁltrating leukocytes in squamous cell carcinoma of the larynx.
Tumors with ≤7 LC/HPF versus tumors with >7L C / H P F ∗
Means values in each group of tumors
Parameter∗∗ ≤7L C / H P F >7 LC/HPF Signiﬁcance
Leucocytes (CD45) 60.5 92.4 P = 0.0037
Macrophages (MO1) 19.07 14.48 P = 0.0291
B cells (IOM-1) 1.69 3.85 P = 0.0234
T cells (CD3) 31.2 51.6 P = 0.0436
Cytotoxic/suppressor
Tc e l l s( C D 8 ) 14.4 25.7 P = 0.0435
Tc e l l / m a c r o p h a g e
ratio (CD3/CD11b) 1.97 3.79 P = 0.0085
CD4/CD8 2 1.2 P = 0.0075
∗Average counting 10 high-power ﬁelds. ∗∗Mean values for number of TIL
or ratios.
4. Discussion
LCs can be readily identiﬁed immunocytochemically in a
large series of human laryngeal tumors even though they
are rare in normal larynx [14]. Although LCs were originally
identiﬁed by silver staining methods, the advent of immuno-
cytochemical techniques and Moabs has considerably aided
their recognition. Antibodies against a variety of diﬀerent
antigens have been successful in demonstrating LCs. Those
against CD1 antigen, such as OKT6 used in this study,
are generally recognized as sensitive in distinguishing LCs
from other cell types in the skin and nonlymphoid tumors
[15, 16]. In particular, they are superior to others like anti-
HLA-DR and anti-S-100 protein, both of which recognize
a number of other cell types such as macrophages or
melanocytes which may cause confusion with LCs. Since
the only other cell labelled by anti-CD1 antibodies is the
immature thymocyte, there is a little chance of any confusion
of LCs with other cell types using these reagents.
In the current series no correlation was found between
number of LCs and parameters of prognostic value. In breast
and uterine carcinomas an association between high number
of LCs and low-stage tumors has been reported [17, 18].
However, similar to our results, in previous series of larynx
carcinomas this association was not found [7]. This suggests
ad i ﬀerent role (immunorecruitment) for these peculiar cells
(see Table 1), more than a ﬁrst line of defence.
Concerning prognosis, it is tempting to speculate that
tumors presenting an increase number of Langerhans cells
would be prone to pursue a more favourable clinical course.
In fact, in gastric carcinoma [3], thyroid carcinoma [4], and
early-stage lung carcinoma [19], numbers of LCs are cor-
related with a better prognosis. However, in larynx carci-
noma positive and negative ﬁndings have been reported
[8, 9]. Our series has a long followup and we were not4 Journal of Oncology
Table 2: Relationship between LCs and clinicopathologic parameters in squamous cell carcinoma of the larynx.
Tumors with ≤7 LC/HPF versus tumors with >7L C / H P F ∗
Parameter ≤7L C / H P F >7 LC/HPF Signiﬁcance
Site
Supraglottic 14 13 N.S
Other sites 9 14
Ts t a g e
I+I I+I I I 1 6 2 2 N.S
IV 7 5
Neck metastasis
Yes 7 9 N.S
No 16 18
Diﬀerentiation
well to moderately diﬀerentiated 18 22 N.S
Poorly diﬀerentiated 6 4
Jakobsson∗∗ 19.4 ± 1.1 18.1 ± 0.9 N.S
Glanz∗∗ 5.5 ± 0.4 5.6 ± 0.4 N.S
∗Average counting 10 high-power ﬁelds. ∗∗Mean value + mean standard error.





Ts t a g e
(IV versus I–III) 4.5 (1.5–14.3) 5.1 (1.5–17.2)
Neck metastasis
Yes versus No 9.5 (2.5–35.5) 8.4 (2.2–31.9)
Jakobsson
>16 versus ≤16 1.9 (1.2–2.9) —
Glanz
>5v e r s u s≤5 5 (1.1–23) —
LCs
>7v e r s u s≤7 1.5 (0.4–5.5) N.S —
O.R: odds ratio, CI: coeﬃcient interval, N.S: nonsigniﬁcant.
able to ﬁnd a relationship with survival. Probably the diﬀer-
ent results in the literature could arise from the diﬀerent
methods of identiﬁcation employed, as not all the studies
used Moabs against CD1 antigen which is considered to be
highly speciﬁc for LCs. We should also consider that cancer
survival is multifactorial and unlikely to be determined by a
single alteration. Therefore, the LC is not a reliable mark-
er to determine prognosis of the patients with laryngeal
squamous cell carcinomas in the clinical practice. However,
it is conceivable that the presence of LCs could enhance the
host immune response against the tumor through the ability
to recruit cytotoxic T lymphocytes.
5. Conclusion
ThenumberofLCsisnotausefultooltodeterminetheprog-
nosis in laryngeal cancer patients but the direct relationship
between LCs and immunomodulatory cells may inﬂuence
the lysis of laryngeal cancer cells.
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